甲状旁腺切除术与西那卡塞在联邦医疗保险投保的肾移植受者中的应用
本研究利用美国肾脏数据系统,纳入2007至2013年首次接受肾移植且投保联邦医疗保险A、B、D部分的患者,排除移植前已行甲状旁腺切除术者,共30,127例。移植后甲状旁腺切除术发生率稳定,而西那卡塞使用增加;长期透析史和移植前使用西那卡塞与两者强相关。约四分之一患者在移植后甲状旁腺切除术后90天内住院,低钙血症相关诊断最常见;甲状旁腺切除术(对比开始西那卡塞)与急性肾损伤增加无关。
要点
- 移植后甲状旁腺切除术发生率稳定,西那卡塞使用在研究期间增加。
- 长期透析史和移植前使用西那卡塞与移植后甲状旁腺切除术及西那卡塞使用强相关。
- 约四分之一患者在移植后甲状旁腺切除术后90天内住院,低钙血症相关诊断最常见。
核心结论
- 近五分之一的研究队列接受了甲状旁腺切除术和/或西那卡塞治疗,需进一步研究以确定移植后甲状旁腺功能亢进的最佳治疗。
研究设计与样本
- 回顾性观察性队列研究,使用美国肾脏数据系统提取2007至2013年首次肾移植且投保联邦医疗保险A、B、D部分的患者数据,排除移植前已行甲状旁腺切除术者,共纳入30,127例。
主要发现
- 共30,127例患者纳入,其中10,707例移植前使用西那卡塞,551例接受移植后甲状旁腺切除术,5,413例填写至少1次西那卡塞处方。
- 移植后甲状旁腺切除术发生率随时间保持稳定,而西那卡塞使用在研究期间增加。
- 长期透析史和移植前使用西那卡塞与移植后甲状旁腺切除术及西那卡塞使用强相关。
- 约四分之一患者在移植后甲状旁腺切除术后90天内住院,低钙血症相关诊断是最常见的并发症。
- 甲状旁腺切除术(对比开始西那卡塞)与急性肾损伤增加无关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏实验室数据以帮助评估继发性/三发性甲状旁腺功能亢进的严重程度。
- 队列仅限于联邦医疗保险受益人。
- 需进一步研究以确定移植后甲状旁腺功能亢进的最佳治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Posttransplant hyperparathyroidism is common, and treatment practices are poorly characterized. The goal of this study was to examine the incidence, associations, and outcomes of posttransplant parathyroidectomy and calcimimetic use in a cohort of Medicare-insured US kidney transplant recipients. STUDY DESIGN: Retrospective observational cohort study. SETTING & PARTICIPANTS: We used the US Renal Data System to extract demographic, clinical, and prescription data from Medicare Parts A, B, and D-insured patients who received their first kidney transplant in 2007-2013. We excluded patients with pretransplant parathyroidectomy. PREDICTORS: Calendar year of transplantation and pretransplant patient characteristics. OUTCOME: (1) Incidence of and secular trends in parathyroidectomy and cinacalcet use in the 3 years after transplant; (2) 90-day outcomes after posttransplant parathyroidectomy and cinacalcet initiation. ANALYTICAL APPROACH: Temporal trends and pretransplant correlates of parathyroidectomy and cinacalcet use were assessed using proportional hazards models and multivariable Poisson regression, respectively. RESULTS: The inclusion criteria were met by 30,127 patients, of whom 10,707 used cinacalcet before transplant, 551 underwent posttransplant parathyroidectomy, and 5,413 filled≥1 prescription for cinacalcet. The rate of posttransplant parathyroidectomy was stable over time. By contrast, cinacalcet use increased during the period studied. Long dialysis vintage and pretransplant cinacalcet use were strongly associated with posttransplant parathyroidectomy and cinacalcet use. Roughly 1 in 4 patients were hospitalized within 90 days of posttransplant parathyroidectomy, with hypocalcemia-related diagnoses being the most common complication. Parathyroidectomy (vs cinacalcet initiation) was not associated with an increase in acute kidney injury. LIMITATIONS: We lacked access to laboratory data to help assess the severity of secondary/tertiary hyperparathyroidism. The cohort was limited to Medicare beneficiaries. CONCLUSIONS: Almost one-fifth of our study cohort was treated with parathyroidectomy and/or cinacalcet. Further studies are needed to establish the optimal treatment for posttransplant hyperparathyroidism.
引用
- Wang AX, Liu S, Montez-Rath ME, et al. Parathyroidectomy and Cinacalcet Use in Medicare-Insured Kidney Transplant Recipients. Am J Kidney Dis. 2022. PMID: 36162617. doi:10.1053/j.ajkd.2022.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。